-
Broncus Medical Inc. Reports 32% YOY Growth in 2023, Highlighted by Strength in China
•
Broncus Medical Inc. (HKG: 2216), a provider of precision intervention solutions for lung diseases with operations in Shanghai and Hangzhou, China, and San Jose and Seattle, United States, has released its financial report for 2023. The company reported product sales of USD 12.41 million for the period, marking a robust…
-
Harbour BioMed Reports Triple-Digit Revenue Growth and First-Ever Net Profit in 2023 Financial Results
•
Harbour BioMed (HKG: 2142), a biopharmaceutical company with a global presence in Suzhou, China, Cambridge in the US, has announced its financial results for the full year of 2023. The company reported a significant leap in revenues, reaching USD 89.5 million, which marks an increase of 119.9% year-on-year (YOY). In…
-
RemeGen Reports 40% Revenue Growth in 2023, but Net Losses Widen Amid Pipeline Investments
•
RemeGen Co., Ltd (HKG: 9995; SHA: 688331), a China-based biotech firm, has unveiled its 2023 financial results, reporting revenues of RMB 1.083 billion (USD 150 million), reflecting a 40.26% year-on-year increase. This growth was primarily driven by its core products: the fusion protein drug telitacicept and the HER2-targeted antibody drug…
-
Everest Medicines Reports 884% Revenue Surge Amid Rising Losses and Strategic Shifts
•
Everest Medicines (HKG: 1952), a China-based biotech company, has released its 2023 annual financial results alongside a corporate update, revealing a staggering 884% year-on-year revenue increase to RMB 125.9 million (USD 17.4 million). However, net losses widened by RMB 597.2 million, reaching RMB 844.5 million. Notably, research and development (R&D)…
-
Luye Pharma Group Posts 2.7% YOY Revenue Growth in 2023 with Strong Market Performance
•
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced its financial performance for 2023, along with recent business updates. The group reported a total revenue of RMB 6.143 billion (USD 850 million), marking a 2.7% year-on-year (YOY) growth. Their oncology, cardiovascular, central nervous system (CNS),…
-
MicroPort CardioFlow Medtech Reports 33.9% YOY Revenue Growth in 2023 Financials
•
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off from China-based MicroPort Scientific Corp (HKG: 0853), has announced its financial report for 2023. The company reported a 33.9% year-on-year (YOY) increase in revenue, reaching RMB 336 million (USD 46.5 million), with gross profits surging 41.8% to RMB 223 million (USD…
-
Ascentage Pharma Reports 5.9% YOY Revenue Growth in 2023, Driven by Product Sales
•
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has released its financial report for 2023, highlighting a total revenue growth of 5.9% year-on-year (YOY) to RMB 222 million (USD 30.7 million). This figure includes product sales amounting to RMB 194 million (USD 26.8 million). The company’s marketing and…
-
CanSino Biologics Reports 2023 Revenue Dip Amid Reduced COVID-19 Vaccine Demand
•
CanSino Biologics (HKG: 6185), a leading Chinese biopharmaceutical company, has released its financial report for 2023, recording revenues of RMB 345.2 million (USD 47.7 million), a decrease of 67% year-on-year (YOY). This decline is primarily attributed to the reduced demand for COVID-19 vaccines, resulting in a RMB 253.2 million refund.…
-
WuXi Bio Reports 2023 Revenue Growth Amid COVID-19 Business Loss and Geopolitical Tensions
•
WuXi Bio (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in China, has released its financial report for 2023, showing a year-on-year (YOY) increase of 11.6% in revenues to RMB 17,034.3 billion (USD 2.35 billion). The company’s net profits reached RMB 3.57 billion (USD 495 million),…
-
Shanghai Fosun Pharma Reports 2023 Revenues, Highlights Innovation and R&D Progress
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based in China, has released its financial report for 2023, recording RMB 41.4 billion (USD 5.73 billion) in revenues, marking a -5.81% year-on-year (YOY) decrease. However, excluding the loss of COVID-19 product sales, the figure shows…
-
National Drug Sampling Inspection Report Reveals High Compliance Rates in 2023
•
The National Institute for Food and Drug Control (NIFDC) has released its “National Drug Sampling Inspection Annual Report (2023),” providing a comprehensive overview of the drug quality surveillance conducted in the past year. The report details the testing of 132 drug varieties, comprising 74 chemical drugs, 43 patented traditional Chinese…
-
Lee’s Pharmaceutical Holdings Ltd Reports 2023 Financials with Focus Shift to Patented and Generic Drugs
•
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a leading pharmaceutical company based in China, has released its financial report for 2023, showing revenues of HKD 1.053 billion (USD 135 million), marking a 14.6% decrease year-on-year (YOY). The gross profit for the period was HKD 551 million (USD 70.4 million), a 28.5%…
-
Hansoh Pharmaceutical Group Reports 7.7% YOY Revenue Growth and Expands R&D Spending
•
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced its financial results for 2023, reporting a 7.7% year-on-year (YOY) increase in revenues to RMB 10.104 billion (USD 1.4 billion). The Chinese pharmaceutical company’s net profits reached RMB 3.278 billion (USD 453.7 million), marking a 26.9% YOY growth. Research and development…
-
Kelun-Biotech Reports Robust 91.6% Revenue Growth Amid Strategic Licensing Efforts
•
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) reported its 2023 financial results, revealing revenues of RMB 1.54 billion (USD 213 million), marking a substantial year-on-year increase of 91.6%, primarily driven by licensing agreements. The company recorded an annual loss of RMB 450 million (USD 62 million), representing a 24.4% reduction…
-
WuXi XDC Reports 114.4% YOY Revenue Growth in 2023, Driven by ADC CRDMO Business
•
WuXi XDC (HKG: 2268), a joint venture between WuXi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has unveiled its financial performance for 2023, reporting revenues of RMB 2.124 billion, marking a significant increase of 114.4% year-on-year (YOY), primarily driven by its antibody…
-
Sanofi Projects EUR 13 Billion in Dupixent Sales for 2024 Despite Q1 Challenges
•
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has released its guidance for the first quarter of 2024. Despite expectations that its top-selling interleukin blocker Dupixent (dupilumab) will face challenges from a co-pay assistance program in the first quarter, the company projects that the drug’s sales will reach EUR 13…
-
Henlius Biotech Posts 67.8% YOY Revenue Growth and First Annual Profit in 2023 Financials
•
Shanghai Henlius Biotech Inc., (HKG: 2696) has released its financial results for 2023, reporting revenues of RMB 5.395 billion (USD 749 million), marking a 67.8% year-on-year (YOY) increase. The company achieved its first profitable full year with net profits reaching RMB 546 million (USD 76 million). The strong financial performance…
-
3SBio Reports 13.8% Revenue Growth in 2023, Driven by Strong Sales of Core Biologics
•
3SBio Inc. (HKG: 1530), a leading China-based biopharmaceutical company, has reported its 2023 financial results, achieving revenues of RMB 7.816 billion (USD 1.09 billion), reflecting a year-on-year (YOY) growth of 13.8%. Net profits rose to RMB 1.952 billion (USD 271 million), an increase of 17.7% YOY. The company’s core biologic…
-
Innovent Biologics Reports 36.2% Revenue Growth in 2023, Highlights Robust Product Sales
•
Innovent Biologics Inc. (HKG: 1801), a China-based biotechnology firm, has released its 2023 financial report, revealing a robust revenue growth of 36.2% year-on-year (YOY) to RMB 6.21 billion (USD 862 million). Product sales constituted RMB 5.73 billion (USD 796 million), marking a 38.4% YOY increase. Despite reporting a loss of…
-
Zuellig Pharma Expands Commercialization Deal for Karo Healthcare’s Lamisil in Asian Markets
•
Zuellig Pharma, a Singapore-based healthcare solutions provider, has announced the expansion of its commercialization agreement with Sweden-based Karo Healthcare. According to the new terms, Zuellig will serve as the exclusive commercialization partner for Karo’s over-the-counter (OTC) anti-fungal treatment Lamisil (terbinafine hydrochloride) across key Asian markets, including Hong Kong, Malaysia, Philippines,…
